Renal cell carcinoma

Current status and future directions

Cynthia L. Martel, Primo N Lara

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Although renal cell carcinoma accounts for only 3% of adult malignancies, it has been increasing in incidence by 2-4% per year since the 1970's. Cigarette smoking, obesity and end-stage renal disease are important risk factors. Genetic syndromes such as von Hippel-Lindau disease are also associated with an increased incidence of renal cell carcinoma. Localized disease should be treated with surgical resection. However, approximately 30% of patients present with metastatic disease. Complete resection of metastases can result in long-term survival in some individuals. Removal of the primary renal tumor in patients with unresectable disseminated disease has also been shown to improve survival in selected good performance status patients receiving systemic immunotherapy. While chemotherapy has been relatively ineffective in the treatment of renal cell carcinoma, biologic therapy with interleukin-2 or interferon does lead to responses in a minority of patients, with occasional long-term survivors. Recently, promising results have been reported with allogeneic stem cell transplantation using a non-myeloablative conditioning regimen. However, therapy for metastatic renal cell carcinoma remains inadequate. Ongoing trials with novel approaches such as anti-angiogenesis agents, cyclin-dependent kinase inhibitors, and tumor vaccines will hopefully lead to improved outcomes in this disease.

Original languageEnglish (US)
Pages (from-to)177-190
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume45
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Renal Cell Carcinoma
von Hippel-Lindau Disease
Cancer Vaccines
Biological Therapy
Survival
Cyclin-Dependent Kinases
Incidence
Stem Cell Transplantation
Immunotherapy
Interferons
Chronic Kidney Failure
Interleukin-2
Survivors
Neoplasms
Obesity
Smoking
Neoplasm Metastasis
Kidney
Drug Therapy
Direction compound

Keywords

  • Clinical trials
  • Renal cell carcinoma
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Renal cell carcinoma : Current status and future directions. / Martel, Cynthia L.; Lara, Primo N.

In: Critical Reviews in Oncology/Hematology, Vol. 45, No. 2, 01.02.2003, p. 177-190.

Research output: Contribution to journalArticle

@article{c44125d7d319477cbc6cc795b61beb2e,
title = "Renal cell carcinoma: Current status and future directions",
abstract = "Although renal cell carcinoma accounts for only 3{\%} of adult malignancies, it has been increasing in incidence by 2-4{\%} per year since the 1970's. Cigarette smoking, obesity and end-stage renal disease are important risk factors. Genetic syndromes such as von Hippel-Lindau disease are also associated with an increased incidence of renal cell carcinoma. Localized disease should be treated with surgical resection. However, approximately 30{\%} of patients present with metastatic disease. Complete resection of metastases can result in long-term survival in some individuals. Removal of the primary renal tumor in patients with unresectable disseminated disease has also been shown to improve survival in selected good performance status patients receiving systemic immunotherapy. While chemotherapy has been relatively ineffective in the treatment of renal cell carcinoma, biologic therapy with interleukin-2 or interferon does lead to responses in a minority of patients, with occasional long-term survivors. Recently, promising results have been reported with allogeneic stem cell transplantation using a non-myeloablative conditioning regimen. However, therapy for metastatic renal cell carcinoma remains inadequate. Ongoing trials with novel approaches such as anti-angiogenesis agents, cyclin-dependent kinase inhibitors, and tumor vaccines will hopefully lead to improved outcomes in this disease.",
keywords = "Clinical trials, Renal cell carcinoma, Treatment",
author = "Martel, {Cynthia L.} and Lara, {Primo N}",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S1040-8428(02)00076-8",
language = "English (US)",
volume = "45",
pages = "177--190",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Renal cell carcinoma

T2 - Current status and future directions

AU - Martel, Cynthia L.

AU - Lara, Primo N

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Although renal cell carcinoma accounts for only 3% of adult malignancies, it has been increasing in incidence by 2-4% per year since the 1970's. Cigarette smoking, obesity and end-stage renal disease are important risk factors. Genetic syndromes such as von Hippel-Lindau disease are also associated with an increased incidence of renal cell carcinoma. Localized disease should be treated with surgical resection. However, approximately 30% of patients present with metastatic disease. Complete resection of metastases can result in long-term survival in some individuals. Removal of the primary renal tumor in patients with unresectable disseminated disease has also been shown to improve survival in selected good performance status patients receiving systemic immunotherapy. While chemotherapy has been relatively ineffective in the treatment of renal cell carcinoma, biologic therapy with interleukin-2 or interferon does lead to responses in a minority of patients, with occasional long-term survivors. Recently, promising results have been reported with allogeneic stem cell transplantation using a non-myeloablative conditioning regimen. However, therapy for metastatic renal cell carcinoma remains inadequate. Ongoing trials with novel approaches such as anti-angiogenesis agents, cyclin-dependent kinase inhibitors, and tumor vaccines will hopefully lead to improved outcomes in this disease.

AB - Although renal cell carcinoma accounts for only 3% of adult malignancies, it has been increasing in incidence by 2-4% per year since the 1970's. Cigarette smoking, obesity and end-stage renal disease are important risk factors. Genetic syndromes such as von Hippel-Lindau disease are also associated with an increased incidence of renal cell carcinoma. Localized disease should be treated with surgical resection. However, approximately 30% of patients present with metastatic disease. Complete resection of metastases can result in long-term survival in some individuals. Removal of the primary renal tumor in patients with unresectable disseminated disease has also been shown to improve survival in selected good performance status patients receiving systemic immunotherapy. While chemotherapy has been relatively ineffective in the treatment of renal cell carcinoma, biologic therapy with interleukin-2 or interferon does lead to responses in a minority of patients, with occasional long-term survivors. Recently, promising results have been reported with allogeneic stem cell transplantation using a non-myeloablative conditioning regimen. However, therapy for metastatic renal cell carcinoma remains inadequate. Ongoing trials with novel approaches such as anti-angiogenesis agents, cyclin-dependent kinase inhibitors, and tumor vaccines will hopefully lead to improved outcomes in this disease.

KW - Clinical trials

KW - Renal cell carcinoma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0037319717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037319717&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(02)00076-8

DO - 10.1016/S1040-8428(02)00076-8

M3 - Article

VL - 45

SP - 177

EP - 190

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -